SUPN Stock - Supernus Pharmaceuticals, Inc.
Unlock GoAI Insights for SUPN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $661.82M | $607.52M | $667.24M | $579.77M | $520.40M |
| Gross Profit | $583.91M | $523.74M | $580.02M | $504.71M | $467.94M |
| Gross Margin | 88.2% | 86.2% | 86.9% | 87.1% | 89.9% |
| Operating Income | $81.67M | $-5,269,000 | $46.12M | $86.03M | $173.70M |
| Net Income | $73.86M | $1.32M | $60.71M | $53.42M | $126.95M |
| Net Margin | 11.2% | 0.2% | 9.1% | 9.2% | 24.4% |
| EPS | $1.34 | $0.02 | $1.13 | $1.01 | $2.41 |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 9th 2025 | Piper Sandler | Upgrade | Overweight | $65 |
| July 30th 2025 | Cantor Fitzgerald | Upgrade | Overweight | $42 |
| February 19th 2025 | Cantor Fitzgerald | Downgrade | Neutral | $36← $57 |
| January 6th 2025 | Cantor Fitzgerald | Initiation | Overweight | $57 |
| September 11th 2024 | Piper Sandler | Downgrade | Neutral | $36← $41 |
| January 3rd 2023 | Jefferies | Resumed | Buy | $45← $44 |
Earnings History & Surprises
SUPNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $0.41 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.82 | $1.01 | +23.2% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $0.47 | $0.91 | +93.6% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $0.38 | $0.42 | +10.5% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $0.46 | $0.75 | +63.0% | ✓ BEAT |
Q4 2024 | Nov 4, 2024 | $0.39 | $1.06 | +171.8% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.31 | $0.36 | +16.1% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.38 | $0.26 | -31.6% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $0.41 | $0.02 | -95.1% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $0.13 | $-0.29 | -323.1% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $0.23 | $-0.02 | -108.7% | ✗ MISS |
Q2 2023 | May 9, 2023 | $0.17 | $0.29 | +70.6% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $0.68 | $0.43 | -36.8% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $0.36 | $0.03 | -91.7% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $0.29 | $0.14 | -51.7% | ✗ MISS |
Q2 2022 | Apr 13, 2022 | $0.24 | $0.04 | -83.3% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $0.24 | $0.04 | -81.3% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $0.23 | $0.40 | +73.9% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $0.20 | $0.43 | +115.0% | ✓ BEAT |
Latest News
Stifel Maintains Hold on Supernus Pharmaceuticals, Raises Price Target to $55
➖ NeutralSupernus Pharmaceuticals shares are trading lower. The company reported Q3 financial results.
📉 NegativeSupernus Pharmaceuticals shares are trading lower. The company reported Q3 financial results.
📉 NegativeSupernus Pharmaceuticals Raises FY2025 Sales Guidance from $670.000M-$700.000M to $685.000M-$705.000M vs $703.277M Est
📈 PositiveSupernus Pharmaceuticals Q3 EPS $(0.80) Beats $(1.10) Estimate, Sales $192.103M Beat $180.523M Estimate
📈 PositiveSupernus Pharmaceuticals shares are trading higher after B of A Securities initiated coverage on the stock with a Buy rating and announced a $65 price target.
📈 PositiveB of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65
📈 PositiveTD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60
📈 PositiveSupernus Pharmaceuticals shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $40 to $65.
📈 PositivePiper Sandler Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to $65
📈 PositiveCantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $63
📈 PositivePiper Sandler Maintains Neutral on Supernus Pharmaceuticals, Raises Price Target to $40
➖ NeutralSupernus to acquire depression drugmaker Sage
📈 PositiveFrequently Asked Questions about SUPN
What is SUPN's current stock price?
What is the analyst price target for SUPN?
What sector is Supernus Pharmaceuticals, Inc. in?
What is SUPN's market cap?
Does SUPN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SUPN for comparison